Adjuvant chemotherapy

Cancer Treatment and Research

Volumn 151, Issue , 2009, Pages 121-137

  Tubiana Hulin, M ^a   Gardner, M ^b  

^a CENTRE RENÉ HUGUENIN   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; LAPATINIB; METHOTREXATE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CARDIOTOXICITY; DRUG EFFICACY; DRUG SAFETY; GONAD DYSFUNCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LUNG TOXICITY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT DURATION;

ANTHRACYCLINES; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS;

EID: 77953682480     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-75115-3_9     Document Type: Review

References (80)

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365(9472):1687-1717
2. Fisher B, Fisher ER, Redmond C. Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol. 1986;4:929-941
3. Bonadonna G, Valagussa P, Tancini G, et al. Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer. NCI Monogr. 1986;4:45-49
4. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1992;339:1-15.
5. Polychemotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;352:930-942
6. Buzdar AU, Kau SW, Smith TL, et al. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol. 1989;12:123-128
7. Bonneterre J, Roche H, Kerbrat P, et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol. 2005;23:2686-2693
8. Hery M, Bonneterre J, Roche H, et al. Epirubicin-based chemotherapy as adjuvant treatment for poor prognosis, node-negative breast cancer: 10-year follow-up results of the French Adjuvant Study Group 03 trial. Bull Cancer. 2006;93:E109-E114.
9. Fisher B, Redmond C, Wickerham DL, et al. Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol. 1989;7(5):572-582 (Pubitemid 19126792)
10. Moliterni A, Bonadonna G, Valagussa P, et al. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol. 1991;9:1124-1130
11. Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen- nonresponsive tumors:Results from theNational SurgicalAdjuvant Breast and Bowel Project B-15. J ClinOncol. 1990;8:1483-1496
12. Misset JL, di Palma M, Delgado M. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: Final report after a 16-year median follow-up duration. J Clin Oncol. 1996;14:1136-1145.
13. Piccart MJ, Di Leo A, Beauduin M, et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol. 2001;19:3103-3110
14. Levine MN, Pritchard KI, Bramwell VH, et al. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol. 2005;23:5166-5170
15. Poole CJ, Earl HM, Hiller L, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med. 2006;355:1851-1862
16. Tancini G, Bonadonna G, Valagussa P, et al. Adjuvant CMF in breast cancer: Comparative 5-year results of 12 versus 6 cycles. J Clin Oncol. 1983;1:2-10.
17. Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle. The Ludwig Breast Cancer Study Group. N Engl J Med. 1988;319:677-683
18. Fumoleau P, Kerbrat P, Romestaing P, et al. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol. 2003;21:298-305.
19. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976-983
20. Hryniuk WM, Goodyear M. The calculation of received dose intensity. J Clin Oncol. 1990;8:1935-1937
21. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med. 1994;330:1253-1259
22. Bonneterre J, Roche H, Bremond A. Results of a randomized trial of adjuvant therapy with FEC 50 versus FEC 100 in high risk node positive breast cancer patients. Proc ASCO 1998;17:473.
23. Fisher B,Anderson S, DeCillis A, et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National SurgicalAdjuvant Breast and Bowel Project B-25.JClinOncol. 1999;17:3374-3388
24. Fisher B, Jeong JH, Dignam J, et al. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr. 2001;30:62-66.
25. Peters WP, Dansey RD, Klein JL, et al. High-dose chemotherapy and peripheral blood progenitor cell transplantation in the treatment of breast cancer. Oncologist. 2000;5:1-13.
26. The Scandinavian breast cancer study group 9401. Results of a randomized adjuvant breast breast cancer study with high dose chemotherapy with CTC [subcript b] supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy. Proc ASCO. 1999;18,A3.
27. Hortobagyi GN, Buzdar AU. RESPONSE: re: randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst. 2000;92:1273.
28. Rodenhuis S, Bontenbal M, Beex LV, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med. 2003;349:7-16. (Pubitemid 36765098)
29. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA. 1995;273:542-547
30. Ferguson T, Wilcken N, Vagg R, et al. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev. 2007;(4):CD004421.
31. Gehl J, Boesgaard M, Paaske T, et al. Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic. Ann Oncol. 1996;7:687-693 (Pubitemid 26323541)
32. Gianni I, Baselga J, Eiermann W, et al. ECTO Study Group European Cooperative Trial in Operable Breast Cancer: Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclosphamide methotrexate and fluorouracil. Proc ASCO. 2005;23,A513.
33. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol. 1995;13:2688-2699
34. Amadori D, Fabbri M. [Doxorubicin and paclitaxel versus 5-fluorouracil, doxorubicin and cyclophosphamide as first-line treatment in women with metastatic breast carcinoma: final results of a phase III multicenter randomized trial]. Tumori. 2001;87:A18-A19.
35. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. J Clin Oncol 2005;23:3686-3696
36. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21:1431-1439
37. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1999;17:2341-2354.
38. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302-2313.
39. Roche H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 Trial. J Clin Oncol. 2006;24:5664-5671.
40. Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006;24:5381-5387
41. Goldstein LJ, O'Neill J, Sparano J, et al. E2197:Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node positive breast cancer. Proc ASCO. 2005;23:A512.
42. O'Shaughnessy J. Gemcitabine combination chemotherapy in metastatic breast cancer: Phase II experience. Oncology (Williston Park). 2003;17:15-21.
43. Poole C. Adjuvant chemotherapy for early-stage breast cancer: the tAnGo trial. Oncology (Williston Park). 2004;18:23-26.
44. Perez E, Muss HB. Optimizing adjuvant chemotherapy in early-stage breast cancer. Oncology (Williston Park). 2005;19:1759-1767
45. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med. 2001;344:1997-2008.
46. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266:1672-1677
47. Steinherz LJ. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1997;126:827-828.
48. Von Hoff DD, Rozencweig M, Layard M, et al. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med. 1977;62:200-208
49. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710-717
50. Keefe DL. Anthracycline-induced cardiomyopathy. Semin Oncol. 2001;28:2-7.
51. Fumoleau P, Roche H, Kerbrat P, et al. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol. 2006;17:85-92.
52. Gianni L, Dombernowsky P, Sledge G, et al. Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer. Ann Oncol. 2001;12:1067-1073.
53. Praga C, Bergh J, Bliss J, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: Correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol. 2005;23:4179-4191
54. Smith RE, Bryant J, DeCillis A, et al. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: The National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol. 2003;21:1195-1204
55. Smith RE. Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: Review of the literature and the National Surgical Adjuvant Breast and Bowel Project experience. Clin Breast Cancer. 2003;4:273-279
56. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series. Blood. 2003;102:43-52.
57. Le Deley MC, Suzan F, Cutuli B, et al. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: Risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol. 2007;25:292-300.
58. Linassier C, Barin C, Calais G, et al. Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy. Ann Oncol. 2000;11:1289-1294
59. Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst. 2007;99:196-205.
60. Muss HB, Berry DA, Cirrincione C, et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: The Cancer and Leukemia Group B Experience. J Clin Oncol. 2007;25:3699-3704.
61. Hudis C, Citron ML, Berry D, et al. Five year follow-up of INT C9741: Dose-dense (DD) chemotherapy (CRx) is safe and effective. Breast Cancer Res Treat. 2005;94:A41.
62. Cooper JA, White DA, Matthay RA. Drug-induced pulmonary disease. Part 1: Cytotoxic drugs. Am Rev Respir Dis. 1986;133:321-340
63. Malik SW, Myers JL, DeRemee RA, et al. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med. 1996;154:1851-1856
64. Koyama H, Wada T, Nishizawa Y, et al. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer. 1977;39:1403-1409
65. Tham YL, Sexton K, Weiss H, et al. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol. 2007;30:126-132.
66. Ganz PA, Desmond KA, Leedham B, et al. Quality of life in long-term, disease-free survivors of breast cancer: A follow-up study. J Natl Cancer Inst. 2002;94:39-49.
67. Kornblith AB, Herndon JE, Weiss RB, et al. Long-term adjustment of survivors of earlystage breast carcinoma, 20 years after adjuvant chemotherapy. Cancer. 2003;98:679-689
68. Andrykowski MA, Curran SL, Lightner R. Off-treatment fatigue in breast cancer survivors: a controlled comparison. J Behav Med. 1998;21:1-18.
69. Bower JE, Ganz PA, Desmond KA, et al. Fatigue in long-term breast carcinoma survivors: A longitudinal investigation. Cancer. 2006;106:751-758.
70. Broeckel JA, Jacobsen PB, Horton J, et al. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol. 1998;16:1689-1696.
71. Goldstein D, Bennett B, Friedlander M, et al. Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: A longitudinal study. BMC Cancer. 2006;6:240.
72. Nieboer P, Buijs C, Rodenhuis S, et al. Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: A longitudinal study. J Clin Oncol. 2005;23:8296-8304
73. Brezden CB, Phillips KA, Abdolell M, et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000;18:2695-2701.
74. Wefel JS, Lenzi R, Theriault RL, et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized, longitudinal trial. Cancer. 2004;100:2292-2299
75. Van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998;90:210-218
76. Cinieri S, Orlando L, Fedele P, et al. Adjuvant strategies in breast cancer: New prospectives, questions and reflections at the end of 2007 St Gallen International Expert Consensus Conference. Ann Oncol. 2007;18:vi63-vi65.
77. Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18:1133-1144
78. Gennari A, Sormani MP, Pronzato P, et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials. J Natl Cancer Inst. 2008;100:14-20.
79. Torrisi R, Balduzzi A, Ghisini R, et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol. 2008;62(4)667-672
80. Goldhirsch A, Gelber RD, Yothers G, et al. Adjuvant therapy for very young women with breast cancer: Need for tailored treatments. J Natl Cancer Inst Monogr. 2001;93:44-51.